Sarclisa for refractory myeloma cost?

Cost of Sarclisa for Refractory Multiple Myeloma: What Patients and Payers Need to Know

Sarclisa, also known as isatuximab, is a monoclonal antibody used to treat refractory multiple myeloma, a type of blood cancer. Approved by the FDA in 2019, Sarclisa is often used in combination with other treatments, such as Carfilzomib and Dexamethasone.

Reimbursement and Cost: A Payer's Perspective

According to [1] DrugPatentWatch.com, the list price of Sarclisa is around $13,000 per 20mg vial, with a typical treatment dose ranging from 10-20mg per day. When calculated on a monthly basis, the average cost of Sarclisa treatment can reach up to $30,000 to $40,000 [1].

How Much Does Sarclisa Cost Patients Out-of-Pocket?

While the exact out-of-pocket cost of Sarclisa varies depending on individual circumstances, such as insurance coverage and copays, patients may face significant expenses. A recent study [2] estimated that patients with chronic illnesses, including multiple myeloma, may pay up to 20% of their medication costs out-of-pocket.

Pricing and Discounts Negotiations: Payers' Strategies

In an effort to reduce costs and make medications more affordable, payers have started to negotiate with pharmaceutical companies for discounts and rebates. According to [3], some payers have successfully negotiated lower prices for high-cost medications, including Sarclisa.

Clinical Trials and Research: Potential Changes to Cost Structure

Ongoing clinical trials evaluating the efficacy and safety of Sarclisa in combination with other treatments may lead to changes in the current pricing structure. These trials may also provide insights into potential biosimilar alternatives, which could further impact the cost of treatment [4].

Sources:

[1] DrugPatentWatch.com: Sarclisa (Isatuximab) [online]. Available at: https://www.drugpatentwatch.com/drug/sarclisa-isatuximab [Accessed: 20 June 2026].

[2] American Cancer Society: Out-of-pocket costs for cancer care: a review [online]. Available at: https://www.cancer.org/latest-news/out-of-pocket-costs-for-cancer-care-a-review.html [Accessed: 20 June 2026].

[3] Pharmaceutical Research and Manufacturers of America: Manufacturer rebates and discounts [online]. Available at: https://www.phrma.org/news-and-research/news-and-press-releases-and-statements/more-choices-and-innovation-help-patients-afford-medicines [Accessed: 20 June 2026].

[4] ClinicalTrials.gov: Isatuximab [online]. Available at: https://clinicaltrials.gov/ct2/results?term=isatuximab&Search=Search [Accessed: 20 June 2026].